[go: up one dir, main page]

AR058293A1 - PROFARMATIC SALTS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIRIMIDIN-5-CARBONIL) -2-METOXI-PHENIL] -3- (2,4- DICLOR-PHENYL) - Google Patents

PROFARMATIC SALTS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIRIMIDIN-5-CARBONIL) -2-METOXI-PHENIL] -3- (2,4- DICLOR-PHENYL)

Info

Publication number
AR058293A1
AR058293A1 ARP060105422A ARP060105422A AR058293A1 AR 058293 A1 AR058293 A1 AR 058293A1 AR P060105422 A ARP060105422 A AR P060105422A AR P060105422 A ARP060105422 A AR P060105422A AR 058293 A1 AR058293 A1 AR 058293A1
Authority
AR
Argentina
Prior art keywords
profarmatic
diclor
isopropil
carbonil
phenil
Prior art date
Application number
ARP060105422A
Other languages
Spanish (es)
Inventor
Tracy Lee Boyden
Douglas Alan Lorenza
Feng Guo
Susan Deborah Lagreca
Franzanne Vreeland
Ravi Mysore Shanker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR058293A1 publication Critical patent/AR058293A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a compuestos de la formula (1) o una sal farmacéuticamente aceptable, profármaco o hidratos de los mismos. La presente también se refiere a composiciones farmacéuticas que contienen los compuestos de formula (1) y a métodos para tratar trastornos hiperproliferativos en un mamífero por medio de la administracion de los compuestos de formula (1).This refers to compounds of the formula (1) or a pharmaceutically acceptable salt, prodrug or hydrates thereof. This also refers to pharmaceutical compositions containing the compounds of formula (1) and to methods for treating hyperproliferative disorders in a mammal by administration of the compounds of formula (1).

ARP060105422A 2005-12-09 2006-12-07 PROFARMATIC SALTS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIRIMIDIN-5-CARBONIL) -2-METOXI-PHENIL] -3- (2,4- DICLOR-PHENYL) AR058293A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74907005P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
AR058293A1 true AR058293A1 (en) 2008-01-30

Family

ID=38123252

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105422A AR058293A1 (en) 2005-12-09 2006-12-07 PROFARMATIC SALTS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIRIMIDIN-5-CARBONIL) -2-METOXI-PHENIL] -3- (2,4- DICLOR-PHENYL)

Country Status (8)

Country Link
AR (1) AR058293A1 (en)
DO (1) DOP2006000271A (en)
GT (1) GT200600496A (en)
NL (1) NL2000337A1 (en)
PE (1) PE20071037A1 (en)
TW (1) TW200733965A (en)
UY (1) UY29991A1 (en)
WO (1) WO2007066189A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922549A (en) * 2007-10-19 2009-06-01 Abbott Gmbh & Amp Co Kg Solid dispersion product containing N-aryl urea-based compound
EP2197425A2 (en) * 2007-10-19 2010-06-23 Abbott GmbH & Co. KG Solid dispersion product of n-aryl urea-based drugs
AU2009305669A1 (en) * 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
BR112012016376A2 (en) 2009-12-30 2019-09-24 Arqule Inc substituted pyrrolo-aminopyrimide compounds
EP2585048B1 (en) * 2010-06-23 2018-04-11 CymaBay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2751112B1 (en) 2011-09-02 2019-10-09 The Regents of The University of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20140004192A1 (en) * 2012-04-13 2014-01-02 Ziopharm Oncology, Inc. Pharmaceutical formulations of indibulin and uses thereof
ES2618003T3 (en) 2012-06-13 2017-06-20 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
EP2900673A4 (en) 2012-09-26 2016-10-19 Univ California MODULATION OF IRE1
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PT2986610T (en) 2013-04-19 2018-03-09 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
KR102632018B1 (en) 2015-02-20 2024-02-02 인사이트 홀딩스 코포레이션 Bicyclic heterocycles as FGFR inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
CN107722012B (en) * 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 Process for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidines
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
BR112020022392A2 (en) 2018-05-04 2021-02-02 Incyte Corporation solid forms of a fgfr inhibitor and processes for preparing them
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
JP7720840B2 (en) 2019-12-04 2025-08-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024522188A (en) 2021-06-09 2024-06-11 インサイト・コーポレイション Tricyclic Heterocycles as FGFR Inhibitors
JP2025015449A (en) * 2023-07-18 2025-01-30 信越化学工業株式会社 Composition for solid dispersion, solid dispersion, and method of manufacturing solid dispersion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837903T2 (en) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Solid pharmaceutical dispersions with increased bioavailability
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives

Also Published As

Publication number Publication date
NL2000337A1 (en) 2007-06-12
DOP2006000271A (en) 2007-08-15
WO2007066189A3 (en) 2008-08-14
PE20071037A1 (en) 2007-11-19
GT200600496A (en) 2007-07-17
TW200733965A (en) 2007-09-16
WO2007066189A2 (en) 2007-06-14
UY29991A1 (en) 2007-07-31

Similar Documents

Publication Publication Date Title
AR058293A1 (en) PROFARMATIC SALTS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIRIMIDIN-5-CARBONIL) -2-METOXI-PHENIL] -3- (2,4- DICLOR-PHENYL)
ECSP055867A (en) PIRROLOPIRIMIDINE DERIVATIVES
NO20085060L (en) Triazole pyrazine derivatives useful as anti-cancer agents
AR056873A1 (en) DERIVATIVES OF PIRAZOLOPIRIMIDINAS AS QUINASA INHIBITORS OF CYCLINE DEPENDENTS, PHARMACEUTICAL COMPOSITIONS
EA201070588A1 (en) DERIVATIVES 1,2,3-TRIAZOLE FOR USE AS STAROIL-COA DESSATRASE AS AN INHIBITORS
AR080491A1 (en) ORAL FORMULATIONS AND LIPOFILIC SALTS OF METHYLNTREXONE
EA200870448A1 (en) PREPARATION OF 1,2,4-TRIAZOLES
ECSP066950A (en) ADRENOCEPTOR-BETA2 GLICOPIRROLATE AND AGONIST COMBINATIONS
EA201000805A1 (en) BIS- (SULFONILAMINO) DERIVATIVES IN THERAPY 066
ECSP066383A (en) DERIVATIVES OF 5-PHENYL-4-METHYL-TIAZOL-2-IL-AMINA AS INHIBITORS OF KINASA ENZYMES PHOSFATIDILINOSITOL 3 (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE RESPIRATORY ROUTES
AR047992A1 (en) DIAMINOPIRIMIDINS AS ANTAGONISTS OF P2X3 AND P2X2 / 3
CY1115176T1 (en) TOLL TYPE RECEPTOR ADJUSTERS
NO20062004L (en) Prolonged release pharmaceutical compositions include aplindor and derivatives thereof
ECSP088549A (en) NEW DERIVATIVES OF FUSIONATED PIRROL
EA201071094A1 (en) TRIPLE-substituted 1,2,4-TRIAZOLES AS MODULATORS OF NICOTINE ACETYL-HOLINE RECEPTORS
ECSP056134A (en) QUINUCLIDINE DERIVATIVES THAT LINK TO M3 MUSCARINIC RECEPTORS
MXPA06002296A (en) Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents.
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
UY30440A1 (en) NEW COMPOUNDS
CO5580767A2 (en) INDAZOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINES AND PROCEDURES FOR USE
UY30460A1 (en) THERAPEUTIC COMPOUNDS
CR9703A (en) DERIVATIVES OF PIRAZOLONA
AR068919A1 (en) 2- [3- (2,2-DIFLUORO-BENZO [1,3] DIOXOL-5-ILAMINO) -5- (2,6-DIMETIL-PIRIDIN-4-IL) [1,2,4] TRIAZOL-1 -IL] -N-ETHYL-ACETAMIDE AND ANALOGS OF THE SAME, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS OF PREPARATION AND USE OF THE SAME IN PSYCHOTIC DISORDERS AND / OR DISEASES WITH INTELLECTUAL DIFFICULTIES.
AR056014A1 (en) COMPOUND 3-AMINOCARBAZOL, PHARMACEUTICAL COMPOSITION CONTAINING IT AND PROCEDURE FOR THE PREPARATION OF THE SAME
UY29510A1 (en) DERIVATIVES OF UREA, METHODS FOR ITS MANUFACTURING, AND USES OF THE SAME

Legal Events

Date Code Title Description
FB Suspension of granting procedure